Churg–Strauss

syndrome ALSANGEDY
 Prodromal stage is
characterized by allergy
BULLETS
 Asthma and/or allergic FOR PACES
rhinitis FOR EASY PASSING PACES FROM
THR 1ST ATTEMPT
 Asthma develops from
Dr. Ibrahim Alsangedy
three to nine years
MRCP-UK
before the other signs
MRCPE
and symptoms
 Nasal polyps and
Sinusitis
 Eosinophilic stage
 Abnormally high level
of eosinophils
 Weight loss, night ALSANGEDY B ULLETS FOR PACES
sweats, cough,
abdominal pain, and
gastrointestinal
bleeding.
 Fever and malaise are
often present.
 Vasculitic stage
 Involves skin, heart, GIT
and kidneys
 Pericardial Tamponade
 Hematuria
Risk stratification Management
 Five-factor score predicts the risk  There is no cure for Churg–
of death in Churg–Strauss ALSANGEDY BULLETS FOR PACES Strauss syndrome
syndrome using clinical
presentations.  The standard treatment is
isangedy@gmail.com
prednisone
 Reduced renal function 00965 69691034
(creatinine >1.58 mg/dl or Facebook page: - MRCP PACES  Immunosuppressive drugs (such
140 µmol/l) from the 1st attempt as azathioprine and
 Proteinuria (>1 g/24h) cyclophosphamide) may reduce
 Gastrointestinal
Facebook group: - MRCP PACES inflammation in people who do
hemorrhage, infarction, or from the 1st attempt not respond well to prednisone
pancreatitis
 Involvement of the central  On December 12, 2017, the FDA
nervous system approved mepolizumab, the first
 Cardiomyopathy Diagnosis drug therapy specifically
indicated for the treatment of
 Criteria for diagnosis of CSS: eosinophilic granulomatosis with
 The lack of any of these factors  Asthma polyangiitis.
indicates milder case, with a five-  Eosinophilia
year mortality rate of 11.9%.  Mononeuropathy or  Patients taking mepolizumab
polyneuropathy experienced a "significant
 The presence of one factor
 Unfixed pulmonary infiltrates improvement" in their symptoms.
indicates severe disease, with a
 Presence of paranasal sinus
five-year mortality rate of 26%
abnormalities
 Histological evidence of
 Two or more indicate very severe
extravascular eosinophils
disease: 46% five-year mortality
rate